文献速递抗栓抗凝管理药物不良反应与药物警戒

艾达珠单抗治疗达比加群相关消化道出血一例

Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran.
PubMed 文献 · Am J Health Syst Pharm · 2018-01-17

本文报告一例77岁男性,因心房颤动并近期行PCI及药物洗脱支架置入,接受阿司匹林、氯吡格雷和达比加群三联抗栓治疗期间发生急性上消化道出血。停用所有抗栓药物后,使用艾达珠单抗逆转达比加群效应,未使用止血药物,24小时后安全行内镜发现Minor Mallory-Weiss撕裂,48小时出院,14周随访时阿司匹林已停用。结论认为艾达珠单抗可成功治疗此类出血。

要点

  • 三联抗栓治疗患者发生急性消化道出血时应停用所有抗栓药物。
  • 艾达珠单抗可用于逆转达比加群的抗凝作用,无需加用止血药物。
  • 逆转后24小时行内镜安全,出血控制后可考虑调整抗栓方案。

核心结论

  • 近期行PCI及支架置入并接受三联抗栓治疗的患者发生急性消化道出血时,使用艾达珠单抗逆转达比加群且未用止血药物可成功治疗。

研究设计与样本

  • 病例报告:1例77岁男性,因急性上消化道出血就诊,接受艾达珠单抗、静脉泮托拉唑及输血治疗。

主要发现

  • 患者三联抗栓方案为阿司匹林、氯吡格雷和达比加群,末次达比加群为就诊前夜,未测血清达比加群水平。
  • 停用所有抗栓药物并给予艾达珠单抗后,24小时后安全行上消化道内镜,发现Minor Mallory-Weiss撕裂。
  • 患者48小时后出院,出院时黑便已缓解,处方抑酸剂及三联抗栓治疗;14周随访时心内科医生已停用阿司匹林。

临床怎么用

  • 对达比加群相关急性消化道出血,可考虑使用艾达珠单抗逆转抗凝作用。
  • 逆转后可根据临床情况安全安排内镜检查,出血控制后需重新评估抗栓方案。

局限性

  • 为单例病例报告,结论不能推广至所有患者。
  • 未测量血清达比加群水平,无法评估抗凝强度与逆转效果的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A case report describing use of idarucizumab for dabigatran reversal without the use of hemostatic agents in a patient who developed acute upper gastrointestinal (GI) bleeding while receiving triple antithrombotic therapy is presented. SUMMARY: A 77-year-old man with a complex cardiac history presented to the emergency room with chief complaints of black tarry stools and low blood pressures for 4 days. His past medical history included recent percutaneous coronary intervention (PCI) and drug-eluting stent (DES) placement, atrial fibrillation, hypertension, hyperlipidemia, coronary artery disease, coronary artery bypass graft surgery, stage 3 chronic kidney disease, and cholecystectomy. His triple antithrombotic therapy consisted of aspirin, clopidogrel, and dabigatran. The patient stated that his last dose of dabigatran was taken the night before. Serum dabigatran levels were not measured. Due to suspicion of acute upper GI bleeding, all antithrombotic agents were withheld. Treatment with idarucizumab, i.v. pantoprazole, and blood transfusion was ordered. An upper endoscopy was safely performed 24 hours later and revealed a minor Mallory-Weiss tear. The patient was discharged 48 hours later with prescriptions for acid suppressant and triple antithrombotic therapy; his melena had resolved before discharge. At 14-week follow-up, the patient reported that his cardiologist had deleted aspirin from his antithrombotic regimen. CONCLUSION: A patient who had recently undergone PCI and DES placement and was receiving aspirin, clopidogrel, and dabigatran for atrial fibrillation was successfully treated for acute GI bleeding with idarucizumab without the use of a hemostatic agent.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Mourafetis J, Doctor N, Leung S, et al. Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran. Am J Health Syst Pharm. 2018. PMID: 29343478. doi:10.2146/ajhp160980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。